DAX24.597 +0,9%Est505.650 +0,6%MSCI World4.352 +0,5%Top 10 Crypto17,29 +1,3%Nas23.043 +1,1%Bitcoin106.085 +1,7%Euro1,1633 -0,2%Öl66,08 +0,5%Gold4.022 -0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Rheinmetall 703000 NVIDIA 918422 BMW 519000 RENK RENK73 Plug Power A1JA81 AMD (Advanced Micro Devices) 863186 Tesla A1CX3T D-Wave Quantum A3DSV9 Siemens Energy ENER6Y HENSOLDT HAG000 Novo Nordisk A3EU6F Diginex A40PU6 NEL ASA A0B733 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX mit neuem Rekordschlussstand -- Wall Street letztlich überwiegend freundlich -- Goldpreis erstmals über 4.000 US-Dollar -- Ottobock, Airbus, DroneShield, PayPal, Plug Power, Diginex, BMW im Fokus
Top News
Setzt Bitcoin zum Jahresendspurt an? Strategy-CEO Michael Saylor zeigt sich nach neuen Rekorden optimistisch Setzt Bitcoin zum Jahresendspurt an? Strategy-CEO Michael Saylor zeigt sich nach neuen Rekorden optimistisch
Sicherer Hafen oder heiße Spekulation: Wohin steuert der Goldpreis? Sicherer Hafen oder heiße Spekulation: Wohin steuert der Goldpreis?
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Akebia Therapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
2,47 EUR -0,08 EUR -2,99 %
BMN
2,86 USD -0,09 USD -3,06 %
BTT
Akebia Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.677,99 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1XF0S

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00972D1054

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAKBA

Akebia Therapeutics Aktien News

DatumMeistgelesen
PR NewswireAkebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
PR NewswireAkebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Secures $55 Million Term Loan Financing
PR NewswireAkebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at Piper Sandler Healthcare Conference
PR NewswireAkebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors
PR NewswireAkebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
PR NewswireAkebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
PR NewswireAkebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
PR NewswireAkebia Therapeutics to Present at H.C. Wainwright Global Investment Conference
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023
PR NewswireAkebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023
PR NewswireAkebia Therapeutics Provides Update on Form 10-Q Filing
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at the H.C. Wainwright Kidney Conference
PR NewswireAkebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients
PR NewswireAkebia Announces Swissmedic Approval of Vafseo® (vadadustat)
PR NewswireAkebia Therapeutics Announces New Chief Financial Officer
PR NewswireAkebia Therapeutics to Present at Jefferies Healthcare Conference
PR NewswireFDA Provides Akebia Therapeutics a Path Forward for Vadadustat
PR NewswireAkebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Aust...

Akebia Therapeutics News

Akebia Therapeutics News: auf dieser Seite finden Sie alle Akebia Therapeutics News und Nachrichten zur Akebia Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Akebia Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Akebia Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.